Unapproved Mexican ibogaine clinics pose safety risks amid FDA acceleration
Unapproved Mexican ibogaine clinics operate without FDA oversight while deaths linked to the compound are documented in medical literature.
Event / Science
Psychedelic Drug FDA Approval Acceleration
President Trump signed an executive order accelerating FDA review of psychedelic drugs including ibogaine, issuing priority vouchers and clearing pathways for first-ever U.S. human trials. The move follows research showing potential therapeutic benefits for PTSD and other conditions, though safety concerns persist.
5 reported locations
Daily activity
0 articles0 articles
2026-08-18 to 2026-11-15 · UTC publication dates
Coverage begins 18 Apr, 17:07 UTC
Follow the documented timeline or explore the related reporting.
What happened
FDA clears pathway for first-ever human trials of ibogaine in United States
The Food and Drug Administration is taking steps to clear the way for the first-ever human trials of ibogaine in the United States. Previously, the National Institutes of Health had briefly funded ibogaine research in the 1990s but discontinued it due to the drug's documented cardiovascular toxicity.
No psychedelics currently approved for medical use in United States
No psychedelic drug has been approved for medical use in the United States. However, several psychedelics including psilocybin, MDMA, and LSD are being studied in large clinical trials for various mental health conditions. All remain illegal and classified as Schedule I substances alongside heroin. Two states—Oregon and Colorado—have legalized psychedelic therapy with psilocybin.
FDA issues national priority vouchers for three psychedelics
The Food and Drug Administration will issue national priority vouchers for three psychedelics the following week. FDA Commissioner Marty Makary stated the vouchers will allow certain drugs to be approved quickly if they align with national priorities. The vouchers can reduce review times from several months to weeks. This marks the first time the FDA has offered fast-tracking approval for any psychedelics.
Trump signs executive order to accelerate FDA review of psychedelic drugs
President Donald Trump signed an executive order directing his administration to speed up reviews of certain psychedelic drugs, including ibogaine, for potential medical use in treating conditions such as severe depression, post-traumatic stress disorder, and opioid addiction. Trump stated the order would help "dramatically accelerate" access to potential treatments and that "if these turn out to be as good as people are saying, it's going to have a tremendous impact."
Ibogaine linked to more than 30 deaths in medical literature
Ibogaine is known to cause irregular heart rhythms and has been linked to more than 30 deaths in medical literature, according to the Multidisciplinary Association for Psychedelic Studies, a nonprofit that conducted early studies on the drug in patients outside the United States.
Stanford study shows veterans treated with ibogaine improved in PTSD and depression symptoms
A Stanford University study found that veterans treated with ibogaine showed improvements in symptoms of traumatic brain injury, including PTSD, depression, and anxiety. The study was small, enrolling 30 veterans who received the drug at clinics in Mexico. Patients received ibogaine mixed with magnesium intended to reduce heart risks. The study did not include a placebo control group.
Ibogaine clinics in Mexico operate without FDA approval
U.S. veterans have reported benefiting from ibogaine after traveling to clinics in Mexico that administer the drug. Beond Ibogaine, a clinic operating in Cancun, Mexico, treated 2,000 people with ibogaine last year at costs between $15,000 and $20,000 per person. The clinic also provided free treatment to approximately 100 veterans. Clinics typically monitor patients' heart readings and maintain emergency medical equipment on hand.
Texas allocates $50 million for ibogaine research
Texas passed a law last year providing $50 million in funding for ibogaine research. This funding was supported by veteran organizations and former Texas Governor Rick Perry, who co-founded Americans for Ibogaine, a group advocating for reducing federal restrictions on the drug.
Read the coverage
2 alternative perspectives
Stanford study reveals ibogaine's promise for veteran PTSD relief
Stanford study documents veterans' PTSD symptom improvement following ibogaine treatment.
FDA Accelerates Psychedelic Drug Review with Executive Action
Federal policy acceleration clears pathway for psychedelic drug trials and research investment.